EGFR and non-small cell lung carcinoma: The standard-of-care for patients with unresectable stage III NSCLC following definitive concurrent chemoradiation is consolidation immunotherapy with durvalumab given the DFS and OS benefit demonstrated by the phase III PACIFIC study and resultant genotype-agnostic FDA and EMA approvals.118–120 However, among patients enrolled in PACIFIC, only 6% had a known EGFR mutation and other oncogenic drivers were not characterized.